Opportunities

The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals to address unmet therapeutic needs through human subjects research. Through this solicitation, the IMA seeks to support human subjects research that is ripe for translation by fostering the clinical development of new or extending the use of existing drugs, vaccines, and companion biomarkers that directly enable drug development. This could be a proof of concept trial for a new medication, a new indication for an existing proprietary or generic drug, or a companion biomarker.  

The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals for projects that address two major challenges in small molecule drug discovery: adaptation of laboratory-grade assays to high-throughput screening (HTS) formats to identify starting points for medicinal chemistry and optimization of lead compounds into drug prototypes.

The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals for projects that address two major challenges in drug development: identification of drug candidates and optimization towards clinical leads. Through this request for proposals, the IMA is soliciting Letters of Intent (LOI) for projects that fall under the protein therapeutics discovery module.

The IMA seeks to support human subjects research that will advance the clinical development of new—or extend the use of existing—medicines, vaccines and diagnostics. This could be a proof-of-concept trial for new medication, a new indication for an existing proprietary or generic drug, or a companion diagnostic tool.

The IMA seeks to support meritorious projects targeted at using patient-derived organoids to develop critical assays for informing the selection of innovative drug candidates. This RFP specifically supports organoids exclusively comprised of epithelial cells, as opposed to those that also contain mesenchymal stroma and/or immune elements. The use of epithelial organoids from any healthy or diseased tissue is allowable.

The Stanford Innovative Medicines Accelerator (IMA) is dedicated to accelerating the prototyping of innovative translational gene and cell therapies that target unmet clinical needs. Basic research is outside the scope of the current RFP solicitation. While new technology development per se is also outside the scope of the RFP, leveraging an emerging technology to therapeutically address a specific clinical need is encouraged.

The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals that address two major challenges in small-molecule drug discovery: identifying medicinal leads and optimizing medicinal leads into drug prototypes. 

Stanford University’s Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines and vaccines, and to enable hypothesis-driven studies in human subjects. The purpose of this request for letters of intent (LOI) is to leverage capacity and infrastructure at Stanford to address unmet medical needs through human subject research.